61 related articles for article (PubMed ID: 1541981)
1. Treatment of recurrent malignant glioma by repeated intracerebral injections of human recombinant interleukin-2 alone or in combination with systemic interferon-alpha. Results of a phase I clinical trial.
Merchant RE; McVicar DW; Merchant LH; Young HF
J Neurooncol; 1992 Jan; 12(1):75-83. PubMed ID: 1541981
[TBL] [Abstract][Full Text] [Related]
2. In vivo regulation of transforming growth factor beta 1 transcription by immunotherapy: interleukin-2 impairs interferon-alpha-stimulated increase in steady-state mRNA levels of transforming growth factor beta 1.
Jahn B; Brieger J; Fenchel K; Mitrou PS; Bergmann L
Cancer Immunol Immunother; 1994 May; 38(5):304-10. PubMed ID: 8162612
[TBL] [Abstract][Full Text] [Related]
3. Postsurgical adjuvant chemoimmunotherapy with recombinant interleukin-2 and 1,3-bis-(2-chloroethyl)-1-nitrosourea on spontaneous metastases of a non-immunogenic murine tumour.
Acerbis G; Cleris L; Rodolfo M; Parmiani G; Formelli F
Cancer Immunol Immunother; 1992; 34(6):383-8. PubMed ID: 1563015
[TBL] [Abstract][Full Text] [Related]
4. Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2.
Kruse CA; Cepeda L; Owens B; Johnson SD; Stears J; Lillehei KO
Cancer Immunol Immunother; 1997 Oct; 45(2):77-87. PubMed ID: 9390198
[TBL] [Abstract][Full Text] [Related]
5. Low-dose recombinant interleukin-2 and low-dose cyclophosphamide in metastatic breast cancer.
Spicer DV; Kelley A; Herman R; Dean G; Stevenson L; Mitchell MS
Cancer Immunol Immunother; 1992; 34(6):424-6. PubMed ID: 1532923
[TBL] [Abstract][Full Text] [Related]
6. The treatment of cancer patients with human lymphoblastoid interferon. A comparison of two routes of administration.
Knost JA; Sherwin SA; Abrams PG; Ochs JJ; Foon KA; Williams R; Tuttle R; Oldham RK
Cancer Immunol Immunother; 1983; 15(2):144-8. PubMed ID: 6307500
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of recombinant interferon gamma administered by s.c. injection three times per week in patients with solid tumours.
Wagstaff J; Smith D; Nelmes P; Loynds P; Crowther D
Cancer Immunol Immunother; 1987; 25(1):54-8. PubMed ID: 3109738
[TBL] [Abstract][Full Text] [Related]
8. The Use of Targeted Cytokines as Cancer Therapeutics in Glioblastoma.
Sooreshjani M; Tripathi S; Dussold C; Najem H; de Groot J; Lukas RV; Heimberger AB
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509400
[TBL] [Abstract][Full Text] [Related]
9. Blockade of inhibitory killer cell immunoglobulin-like receptors and IL-2 triggering reverses the functional hypoactivity of tumor-derived NK-cells in glioblastomas.
Sönmez C; Wölfer J; Holling M; Brokinkel B; Stummer W; Wiendl H; Thomas C; Schulte-Mecklenbeck A; Grauer OM
Sci Rep; 2022 Apr; 12(1):6769. PubMed ID: 35474089
[TBL] [Abstract][Full Text] [Related]
10. History and current state of immunotherapy in glioma and brain metastasis.
McGranahan T; Li G; Nagpal S
Ther Adv Med Oncol; 2017 May; 9(5):347-368. PubMed ID: 28529551
[TBL] [Abstract][Full Text] [Related]
11. Oral Administration of Interleukin-10 and Anti-IL-1 Antibody Ameliorates Experimental Intestinal Inflammation.
Cardani D; Dusio GF; Luchini P; Sciarabba M; Solimene U; Rumio C
Gastroenterology Res; 2013 Aug; 6(4):124-133. PubMed ID: 27785242
[TBL] [Abstract][Full Text] [Related]
12. Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment.
Jackson C; Ruzevick J; Phallen J; Belcaid Z; Lim M
Clin Dev Immunol; 2011; 2011():732413. PubMed ID: 22190972
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cell therapy of high-grade gliomas.
Van Gool S; Maes W; Ardon H; Verschuere T; Van Cauter S; De Vleeschouwer S
Brain Pathol; 2009 Oct; 19(4):694-712. PubMed ID: 19744041
[TBL] [Abstract][Full Text] [Related]
14. Imaging correlates of differential expression of indoleamine 2,3-dioxygenase in human brain tumors.
Batista CE; Juhász C; Muzik O; Kupsky WJ; Barger G; Chugani HT; Mittal S; Sood S; Chakraborty PK; Chugani DC
Mol Imaging Biol; 2009; 11(6):460-6. PubMed ID: 19434461
[TBL] [Abstract][Full Text] [Related]
15. Somnolence syndrome after focal radiation therapy to the pineal region: case report and review of the literature.
Kelsey CR; Marks LB
J Neurooncol; 2006 Jun; 78(2):153-6. PubMed ID: 16575537
[TBL] [Abstract][Full Text] [Related]
16. Verotoxins inhibit the growth of and induce apoptosis in human astrocytoma cells.
Arab S; Murakami M; Dirks P; Boyd B; Hubbard SL; Lingwood CA; Rutka JT
J Neurooncol; 1998 Nov; 40(2):137-50. PubMed ID: 9892096
[TBL] [Abstract][Full Text] [Related]
17. Intrathecal immunotherapy in CNS tumors disseminating via CSF: preliminary evaluation using different treatment schedules.
Salmaggi A; Dufour A; Silvani A; Ciusani E; Nespolo A; Boiardi A
Ital J Neurol Sci; 1996 Aug; 17(4):267-76. PubMed ID: 8915757
[TBL] [Abstract][Full Text] [Related]
18. Immune adjuvants for chemotherapy or radiotherapy in the 9L rat brain tumor model.
Liu C; Kimler BF; Evans RG; Morantz RA
J Neurooncol; 1993 Feb; 15(2):113-23. PubMed ID: 8509816
[TBL] [Abstract][Full Text] [Related]
19. Effects of route and formulation on clinical pharmacokinetics of interleukin-2.
Anderson PM; Sorenson MA
Clin Pharmacokinet; 1994 Jul; 27(1):19-31. PubMed ID: 7955769
[TBL] [Abstract][Full Text] [Related]
20. Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients.
Boiardi A; Silvani A; Ruffini PA; Rivoltini L; Parmiani G; Broggi G; Salmaggi A
Cancer Immunol Immunother; 1994 Sep; 39(3):193-7. PubMed ID: 7923250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
